Neutrophil: A New Player in Metastatic Cancers

Wu, Mengyue; Ma, Mutian; Tan, Zhenya; Zheng, Hong; Liu, Xia

doi:10.3389/fimmu.2020.565165

Cited by 84 publications

(61 citation statements)

References 151 publications

(178 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As stated before in this manuscript, the NLR ratio is becoming a reliable biomarker for prognostic and predictive stratification in NSCLC ( Boscolo et al, 2020 ). Moreover, PMNs are recruited to distant organs through CXCR2/4 signaling and foster pre-metastatic niche formation ( Wu, 2020 ).…”

Section: Neutrophil Recruitment and Function In Lung Cancermentioning

confidence: 99%

Frontiers in Pharmacology: Review Manuscript Targeting of the Neutrophil as an Adjunctive Strategy in Non-Small Cell Lung Cancer

2021

View full text Add to dashboard Cite

Lung cancer remains the leading cause of cancer mortality in the United States, with non-small cell lung cancer (NSCLC) accounting for around 85% of cases. Of particular concern is the poor responsiveness of this malignancy to therapy, resulting in a very low 5-year survival rate (17.4%) and a prominent tendency to progress to metastatic disease. A number of very recent studies, both pre-clinical and clinical, have implicated the neutrophil in both the pathogenesis and unsatisfactory response to therapy of NSCLC. In this context, movement of neutrophils into the tumor microenvironment (TME) is a common feature of NSCLC. Indeed neutrophils are the dominant type of immune cell in the NSCLC TME, creating a highly immunosuppressive milieu that is not only conducive to tumor growth and spread, but also represents a significant obstacle to the success of anti-tumor therapy, especially novel immunotherapies. The clinically relevant adverse impact of a neutrophil predominance both systemically and in the TME of patients with NSCLC is underscored by the negative prognostic value of both a persistent neutrophilia and, in particular, a high (≥5) neutrophil:lymphocyte ratio. On a more positive note, however, recognition of the involvement of the neutrophil in both the pathophysiology of NSCLC and treatment failure has enabled identification of neutrophil-targeted strategies that have the potential to serve as adjuncts to standard anti-cancer therapies, including immunotherapy. These strategies together with a consideration of the immunosuppressive, pro-tumorigenic properties of the neutrophil represent the major thrusts of this review.

show abstract

Section: Neutrophil Recruitment and Function In Lung Cancermentioning

confidence: 99%

Frontiers in Pharmacology: Review Manuscript Targeting of the Neutrophil as an Adjunctive Strategy in Non-Small Cell Lung Cancer

2021

View full text Add to dashboard Cite

show abstract

“…As noted, although DTCs can migrate as single cells, collective migration is a more efficient route for metastasis [ 61 ]. Tumor-associated neutrophils and macrophages (TAMs), as well as myeloid-derived suppressor cells (MDSCs), promote collective migration and intravasation of tumor cells [ 33 , 62 , 63 ]. Under the influence of colony-stimulating factor 1 (CSF1), TAMs also promote angiogenesis.…”

Section: The Tumor Microenvironmentmentioning

confidence: 99%

Progression to Metastasis of Solid Cancer

Zacksenhaus

Egan

2021

Cancers

View full text Add to dashboard Cite

show abstract

“…The role of neutrophils in the pre-metastatic niche has not been fully explored. Neutrophils are innate immune cells that maintain tissue homeostasis by adjusting their function in response to various stimuli [121,122] . Although initially thought to not play an active role in cancer development, through the use of preclinical models, it has been demonstrated that different subpopulations of neutrophils modulate cancer metastasis [123] .…”

Section: Resident Cell Contributions To the Establishment Of The Brain Premetastatic Nichementioning

confidence: 99%

Breast-to-brain metastasis: a focus on the pre-metastatic niche

Malone¹,

Tsirka²

2021

JCMT

View full text Add to dashboard Cite

Metastatic disease is the cause for 90% of breast cancer mortalities. For those 10%-20% of patients whose breast cancer metastasizes to the central nervous system, the one-year survival rate is just 20%. Both histology and molecular subtype have a correlation with the site of tumor metastasis, indicating an inherent preferential aspect to metastatic colony formation. The molecular differences between breast cancers may determine the site of metastasis through priming of the premetastatic niche in that site: cell surface molecules, exosomes released from the primary tumor, and soluble factors secreted from both the primary tumor and resident cells within the premetastatic niche all contribute to altering the premetastatic niche to be more favorable for the circulating tumor cells, allowing for cell invasion and growth. Here, we review breast to brain metastasis with a focus on the premetastatic niche. We discuss the secreted factors and exosomes that prime the premetastatic niche within the brain by instigating crosstalk between the resident cells of the brain microenvironment. We report on the individual roles that microglia, astrocytes, pericytes, neurons, and endothelial cells may have in the formation and maintenance of the premetastatic niche.

show abstract

Neutrophil: A New Player in Metastatic Cancers

Cited by 84 publications

References 151 publications

Frontiers in Pharmacology: Review Manuscript Targeting of the Neutrophil as an Adjunctive Strategy in Non-Small Cell Lung Cancer

Frontiers in Pharmacology: Review Manuscript Targeting of the Neutrophil as an Adjunctive Strategy in Non-Small Cell Lung Cancer

Progression to Metastasis of Solid Cancer

Breast-to-brain metastasis: a focus on the pre-metastatic niche

Contact Info

Product

Resources

About